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Background. The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children. Current efforts to enhance 
RTS,S/AS01E efficacy would benefit from learning about the vaccine-induced immunity and identifying correlates of malaria pro-
tection, which could, for instance, inform the choice of adjuvants. Here, we sought cellular immunity-based correlates of malaria 
protection and risk associated with RTS,S/AS01E vaccination.
Methods. We performed a matched case-control study nested within the multicenter African RTS,S/AS01E phase 3 trial. 
Children and infant samples from 57 clinical malaria cases (32 RTS,S/25 comparator vaccinees) and 152 controls without malaria 
(106 RTS,S/46 comparator vaccinees) were analyzed. We measured 30 markers by Luminex following RTS,S/AS01E antigen stimula-
tion of cells 1 month postimmunization. Crude concentrations and ratios of antigen to background control were analyzed.
Results. Interleukin (IL) 2 and IL-5 ratios were associated with RTS,S/AS01E vaccination (adjusted P  ≤ .01). IL-5 circumsporo-
zoite protein (CSP) ratios, a helper T cell type 2 cytokine, correlated with higher odds of malaria in RTS,S/AS01E vaccinees (odds 
ratio, 1.17 per 10% increases of CSP ratios; P value adjusted for multiple testing = .03). In multimarker analysis, the helper T cell type 
1 (TH1)–related markers interferon-γ, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent 
malaria, in contrast to IL-5 and RANTES, which increased the odds of malaria.
Conclusions. RTS,S/AS01E-induced IL-5 may be a surrogate of lack of protection, whereas TH1-related responses may be 
involved in protective mechanisms. Efforts to develop second-generation vaccine candidates may concentrate on adjuvants that 
modulate the immune system to support enhanced TH1 responses and decreased IL-5 responses.
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RTS,S/AS01E is the most advanced malaria vaccine candidate in 
development, having completed a phase 3 trial in Africa, in which 
the 1-year vaccine efficacy (VE) against clinical malaria was 56% 
in children aged 5–17 months and 31% in infants aged 6–12 weeks 
[1–3]. The mechanisms of RTS,S/AS01E-induced protection and 
the reasons for the moderate efficacy and the lower protection 
in infants than children remain unclear. Identifying immune 
correlates of protection can shed light on these questions, help 
improve RTS,S/AS01E, and rationally design the next generation 
of malaria vaccines to control and eliminate this disease.
RTS,S is a subunit vaccine targeting the pre-erythrocytic stage 
of Plasmodium falciparum infection and is based on the circum-
sporozoite protein (CSP). The vaccine consists of a recombinant 
protein containing part of the CSP fused to and coexpressed 
with the hepatitis B surface antigen (HBsAg). RTS,S in the phase 
3 trial was formulated with the AS01 adjuvant that consists of 
3-O-desacyl-4′-monophosphoryl lipid A (MPL), QS21, and lipos-
omes. In previous trials, RTS,S induced high titers of anti-CSP 
immunoglobulin G (IgG) [4–10], which recently were shown to 
correlate with the magnitude and duration of VE in children and 
infants [11, 12]. Unlike antibodies, cellular responses in endemic 
areas are low to moderate and mainly based on helper T cell type 1 
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(TH1) responses, specifically CD4
+ T cells expressing, interleukin 
(IL) 2, tumor necrosis factor (TNF), and interferon (IFN)–γ [4–9]. 
No investigated cellular response has predicted RTS,S-induced 
protection consistently in pediatric phase 2 trials [7, 8].
RTS,S/AS01E-induced cellular immunity is probably com-
plex and involves different cell types and immune mediators. 
Most studies performed to date measured a limited number 
of parameters, restricted by the reduced amounts of blood 
obtained in children. Multiplex bead arrays and the Luminex 
platform allow multiparameterization of numerous markers 
in small volumes. Use of this technology in 2 studies includ-
ing a limited number of markers suggested that RTS,S vacci-
nation elicited secretion of the cytokines IL-2 and IL-4 [4, 9]. 
Herein, we used a multiplex immunoassay to measure cellular 
responses following ex vivo stimulations with vaccine antigens 
in cells freshly isolated at pre- and postimmunization in chil-
dren and infants from 3 African sites of the phase 3 trial.
METHODS
Study Design
Written informed consent was obtained from children’s par-
ents/guardians before recruitment. The study protocol was 
approved by all relevant ethics review boards and national 
regulatory authorities (Supplementary Methods). We per-
formed a matched case-control study nested within the RTS,S/
AS01E phase 3 trial, described elsewhere [3]. In brief, the trial 
enrolled infants (6–12 weeks) and children (5–17 months) 
who were vaccinated with either RTS,S/AS01E or a compara-
tor vaccine—that is, rabies vaccine (children) or meningo-
coccal C conjugate vaccine (infants), administered at study 
months zero, 1, and 2. Peripheral blood mononuclear cells 
(PBMCs) were collected and stimulated ex vivo at month 0 
before vaccination and 30 days after the third dose of vaccine 
(M3) from 368 children in 3 trial sites: Bagamoyo (Tanzania), 
Lambaréné (Gabon), and Manhiça (Mozambique); and from 
219 infants in Manhiça and Lambaréné (only M3). This study 
included all malaria cases detected 1–12 months postvacci-
nation from the according-to-protocol immunology cohort 
whose samples were available (Figure 1 , Supplementary Table 
1). Malaria cases were defined as subjects who sought care at 
a health facility and had any P. falciparum asexual parasitemia 
by blood smear. Controls were matched to cases based on site, 
age group, and time of vaccination and follow-up. Up to 1:4 
case:controls (average 1:3) were selected among RTS,S/AS01E 
vaccinees, and 1:2 case:controls were selected among com-
parator vaccinees. Investigators conducted assays blinded to 
vaccination and protection status.
Peripheral Blood Mononuclear Cell Stimulations and Multiplex Bead 
Array Assay
PBMCs were stimulated fresh with peptide pools covering the 
2 vaccine antigens: CSP (31 peptides) and HBsAg (53 peptides) 
[7]. Dimethyl sulfoxide, the solvent for peptide pools, was used 
alone as a background control (henceforth “background” or 
“mock stimulation”). Thirty cytokines, chemokines, and growth 
factors were quantitated in cell supernatants using the Cytokine 
Human Magnetic Panel from Life Technologies (Supplementary 
Methods).
Selection of Markers and Metrics for Primary Analysis in a Pilot Study
Four cytokines (IL-2, IL-5, IL-17, and IFN-γ) were selected as 
primary markers for primary and secondary analyses in a pilot 
study that included 153 children who were not in the main 
matched case-control study. Markers were selected based on 
immunogenicity (Supplementary Table 2), precision, reliability, 
accuracy, uniqueness, and biological relevance. The primary 
outcome for antigen-specific responses was defined in the pilot 
study as the ratio between the crude concentration after anti-
gen stimulations (CSP or HBsAg) and after mock stimulations 
(Supplementary Methods).
Statistical Analysis
Primary analysis of immunogenicity and correlates of protec-
tion was based on ratios of primary markers at M3 and focused 
on RTS,S/AS01E vaccinees and CSP responses. To distinguish 
correlates of RTS,S/AS01E-induced immunity from correlates 
of naturally acquired immunity, results of RTS,S/AS01E and 
comparator vaccinees were contrasted through interaction tests 
with vaccination group.
Marker responses between RTS,S/AS01E and comparator 
vaccinees were contrasted through linear models and t tests. 
Impact of baseline ratios on postvaccination ratios was assessed 
through linear regression models, with baseline ratios as predic-
tors. Analyses of correlates of protection were based on compar-
isons of cases and controls for CSP ratios in logistic regression 
models with a random intercept to account for matching strata. 
Odds ratios (ORs) were scaled to represent a 10% increase in 
ratios or in concentrations. Additionally, for interpretability, rel-
evant ORs were scaled based on standard deviations. To identify 
groups of markers associated with malaria, marker ratios were 
analyzed in combination and selected through regression with 
elastic net and through partial least squares discriminant anal-
ysis (PLS-DA).
All tests were 2-sided and considered statistically significant 
to a .05  α-level. Analyses were adjusted for multiple testing 
through permutation (maximum T). P values for the 4 primary 
markers were adjusted (P-adj) separately from the 24 second-
ary markers. P values for CSP and HBsAg stimulations were 
adjusted separately. Adjustments for multiple testing when 
assessing interactions with vaccination status, age group, or sex 
were done through Holm (primary markers) and Benjamini-
Hochberg (secondary markers) approaches. When age interac-
tions were statistically significant, the age-specific association 
was reported. Analyses were conducted using the R software 
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1137 RTS,S/AS01E vaccinees 
705 children/ 432 infants 
584 comparator vaccinees 
371 children/ 213 infants 
709 vaccinees had PBMC  
413 children/ 296 infants 
382 vaccinees had PBMC 
228 children/ 154 infants 
372  vaccinees had  
PBMC stimulations 
236 children/ 137 infants‡ 
32 cases analyzed 
16 children/16 infants 
106 controls analyzed§ 
53 children/53 infants 
25 cases analyzed 
17 children/8 infants 
46 controls analyzed§ 
30 children/16 infants 
428 not selected for 
cellular component* 
  
14 children had M0 
samples available 
46 children had M0 
samples available 
12 children had M0 
samples available 
202 not selected for 
cellular component* 
  
18 children had M0 
samples available 
 210 vaccinees had  
PBMC stimulations 
131 children/ 79 infants‡ 
193 had < 6.6 
million cells 
97 were included in 
a separate B-cell study 
47 had missing 
samples   
32 cases by M12† 
16 children/16 infants 
341 controls by M12 
220 children/121 infants 
188 controls by M12 
117 children/71 infants 
109 had < 6.6 
million cells 
41 were included in 
a separate B-cell study
22 had missing 
samples 
  
25 cases by M12† 
17 children/8 infants 
9 did not meet inclusion 
criteria for the clinical trial 
341 excluded 
56 did not receive 3 doses of    
the study vaccine 
192 did not comply with 
primary vaccination 
schedule 
82 had blood collected 
outside of the period 
specified in the protocol 
11 other reason  
1721 subjects were included in the M067 ATP criteria for 
Bagamoyo, Lambaréné and Manhiça  
 
4272 subjects enrolled in the ITT phase 3 RTS,S/AS01E 
Trial (M055) for Bagamoyo, Lambaréné and Manhiça 
2071 subjects were included in the M067 ITT cohort for 
Bagamoyo, Lambaréné and Manhiça  
 
RTS,S/AS01E Comparator 
Figure 1. Study profile. *Based on the study protocol, only a subset of vaccinees were enrolled for the cellular component of the immunology study MAL067 (M067), 
ancillary to the RTS,S/AS01E phase 3 trial MAL055 (M055). ‡Per study protocol, peripheral blood mononuclear cells (PBMCs) were supposed to be freshly stimulated and 
have supernatant collected whenever >6.6 million cells were harvested. The priority was to cryopreserve 5 million PBMCs. Stimulations were performed when additional 
PBMCs were available for at least circumsporozoite protein and mock stimulations (0.8 million each). In the Manhiça site, after we collected samples from 292 subjects in 
each age cohort, all subsequent samples were assigned to a different study involving B cells and no fresh stimulations were performed. †Four subjects (1 RTS,S/AS01E- and 
3 comparator-vaccinated children) who were not originally in the according-to-protocol cohort were inadvertently included in the analysis. The subjects had the blood sample 
collected more than the 30 days after the primary vaccination defined in the protocol. §Up to 1:4 case:controls (average 1:3) were selected among RTS,S/AS01E vaccinees, 
and 1:2 case:controls were selected among comparator vaccinees. Controls that were not matched to any case were not analyzed. Abbreviations: ATP, according-to-protocol; 
ITT, intention-to-treat; M0, study month 0; M12, study month 12; PBMC, peripheral blood mononuclear cell. 
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package [13]. Secondary analysis and details are described in 
the Supplementary Methods.
RESULTS
Study Population and Markers at Preimmunization
Samples from 209 subjects were analyzed (Figure  1). Among 
RTS,S/AS01E vaccinees, 15 cases and 51 controls were from 
Bagamoyo, 1 case and 2 controls from Lambaréné, and 16 cases 
and 53 controls from Manhiça. Vaccinees in Bagamoyo and 
Lambaréné were all children, and in Manhiça nearly all were 
infants (95%). Preimmunization CSP ratios in RTS,S/AS01E- 
and comparator-vaccinated children (baseline samples were not 
collected in infants) were comparable, except for IFN-γ, which 
was statistically significantly higher in RTS,S/AS01E vaccinees 
(Supplementary Table 3).
Immunogenicity Markers
When comparing CSP ratios between RTS,S/AS01E and com-
parator vaccinees at M3, only IL-2 was significantly higher 
in RTS,S/AS01E than in comparator vaccinees (Figure 2A, 
Supplementary Figure 1A). For HBsAg ratios, IL-2 and the 
helper T cell type 2 (TH2) cytokine IL-5 were significantly 
higher in RTS,S/AS01E vaccinees (Figure 2B, Supplementary 
Figure 1B). The effect of vaccination on ratios was comparable 
in children and infants and in both sexes (P-adj > .10 for inter-
action with age and with sex).
Concentrations of primary markers IL-2 and IL-5 after CSP 
and HBsAg stimulations were significantly higher in RTS,S/
AS01E than in comparator vaccinees (Supplementary Figure 2). 
Unlike analysis with ratios, concentrations after CSP, HBsAg, and 
mock stimulations were different between age groups for several 
markers (P-adj for interaction with age <.05; Supplementary 
Table  4). In children, CSP and background responses of most 
of these markers were higher in RTS,S/AS01E vaccinees than 
in comparator vaccinees, including the TH1-related cytokines 
IFN-γ, IL-12, IL-15, and the proinflammatory markers TNF 
and IL-1β (Table 1; Supplementary Table 4). In contrast, no dif-
ferences in marker concentrations between vaccination groups 
were detected in infants. No differences in immunogenicity by 
sex were found (P-adj > .10 for interaction with sex).
Impact of Preimmunization Markers on RTS,S/AS01E Immunogenicity
Baseline responses to CSP due to previous immunity or to 
HBsAg due to hepatitis B vaccination (included in the expanded 
program of immunization) could affect immunogenicity of 
RTS,S/AS01E in children. Therefore, we analyzed the impact 
of prevaccination ratios of primary markers on the postvacci-
nation ratio of the same or any other marker (Supplementary 
Table 5). For CSP ratios in RTS,S/AS01E-vaccinated children, 
baseline IFN-γ was consistently and positively correlated with 
postvaccination ratios of some markers, including the immu-
nogenicity marker IL-2, the TH1-related cytokine IL-15, and 
the homeostatic cytokine IL-7 (Supplementary Figure  3). For 
HBsAg ratios, baseline IFN-γ was negatively correlated with 
some postvaccination CSP ratios, including IFN-α, IFN-γ, 
and vascular endothelial growth factor (VEGF). Baseline IL-2 
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Figure  2. Circumsporozoite protein (CSP; A) or hepatitis B surface antigen 
(HBsAg; B) primary marker ratios 1 month postimmunization with RTS,S/AS01E or 
a comparator vaccine. Diamonds show geometric means of CSP or HBsAg ratios 
to controls and bars show the 95% confidence intervals. P values were computed 
through t tests of the log10-transformed ratios and were adjusted for multiple test-
ing (P-Adj) through a permutation approach. Only statistically significant P values 
are shown. There were 137 RTS,S/AS01E and 70 comparator vaccinees for CSP (A) 
and 133 RTS,S/AS01E and 63 comparator vaccinees for HBsAg (B). Abbreviations: 
CSP, circumsporozoite protein; HBsAg, hepatitis B surface antigen; IFN-γ, interferon 
gamma; IL, interleukin.
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HBsAg ratios correlated with higher levels of some postvacci-
nation CSP ratios (eg, IFN-α). Few baseline HBsAg ratios were 
associated with postvaccination HBsAg ratios in RTS,S/AS01E 
vaccinees (Supplementary Table  5), and most associations 
were weak and different from associations with CSP ratios. In 
contrast, no clear associations were detected in comparator 
vaccinees.
Correlates of Clinical Malaria: Single-Marker Analysis
Figure 3 shows the ORs for 10% increases in postvaccination CSP 
ratios of primary and secondary markers and malaria in RTS,S/
AS01E (Figure 3A) and comparator vaccinees (Figure 3B). 
Only IL-5 was significantly associated with the odds of malaria 
in RTS,S/AS01E vaccinees (OR, 1.17 per 10% increases of IL-5 
CSP ratios [95% confidence interval, 1.03–1.38]). Although the 
Table 1. Comparisons of Marker Concentrations After Circumsporozoite Protein Stimulations in RTS,S/AS01E and Comparator Vaccinees by Age Cohort 
When Significant Age Interactions Were Detected
Children Infants Difference Age Groups
Marker RTS,S/AS01E (n = 69) Comparator (n = 47) P Valuea RTS,S/AS01E (n = 69) Comparator (n = 24) P Valuea P Valueb Adjusted P Valueb
IFN-γ 36 (24–54) 15 (10–25) .008 11 (7–16) 10 (4–22) .88 .002 .007
G-CSF 1314 (1081–1598) 885 (658–1190) .03 629 (511–774) 693 (452–1062) .69 <.001 <.001
GM-CSF 345 (265–451) 159 (98–258) .007 145 (104–201) 149 (71–313) .95 <.001 <.001
IL-10 337 (260–437) 180 (112–289) .03 128 (98–166) 164 (93–290) .44 <.001 <.001
IL-12 2090 (1650–2647) 1094 (739–1619) .007 841 (687–1029) 811 (533–1232) .88 <.001 <.001
IL-15 162 (137–191) 104 (81–134) .005 110 (96–127) 110 (73–168) 1 .01 .03
IL-1β 2491 (2142–2898) 1285 (833–1984) .007 1210 (1019–1438) 1145 (792–1656) .79 <.001 <.001
IL-1RA 3422 (2763–4238) 2166 (1605–2924) .02 1653 (1400–1952) 1505 (913–2479) .73 <.001 <.001
IP-10 32 (27–40) 26 (22–30) .07 23 (20–25) 22 (17–28) .85 .003 .009
TNF 1297 (1035–1625) 521 (303–898) .004 287 (193–425) 316 (168–594) .8 <.001 <.001
Data are presented as geometric mean, pg/mL (95% confidence interval) unless otherwise indicated.
Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon gamma; IL, interleukin; IP, interferon-gamma- 
induced protein; TNF, tumor necrosis factor.
aP values for the comparison of RTS,S and comparator vaccinees were computed based on t tests of log10-transformed values.
bP values for assessing differences between age cohorts (interaction with age) were computed through linear regressions and were adjusted for multiple testing using a Holm approach for 
primary markers and a Benjamini-Hochberg approach for secondary markers.
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Figure 3. Correlation between clinical malaria and circumsporozoite protein (CSP) marker ratios in RTS,S/AS01E vaccinees (A) and comparator vaccinees (B). Odds ratios 
and 95% confidence intervals per 10% increase in primary and secondary marker ratios (CSP ratio to control) 1 month postimmunization. Blue indicates markers that were 
significantly associated (without adjustment for multiple testing) with clinical malaria in logistic mixed-effects models. P values were adjusted (P-Adj) for multiple testing 
through a permutation approach. N = 137 RTS,S/AS01E vaccinees and 70 comparator vaccinees. *The association between clinical malaria and the interleukin 5 ratios was 
different between RTS,S/AS01E and comparator vaccinees, with P value for interaction test adjusted for multiple testing = .049. Abbreviations: EGF, epidermal growth factor; 
FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN, 
interferon; IL, interleukin; IP, interferon-gamma-induced protein; MCP, monocyte chemoattractant protein; MIG, monokine induced by IFN-γ; MIP, macrophage inflammatory 
protein; OR, odds ratio; RANTES, regulated on activation normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. 
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chemokine RANTES (regulated on activation normal T-cell 
expressed and secreted) was also associated with increased odds 
of malaria in RTS,S/AS01E vaccinees (OR, 1.09 [confidence 
interval, 1.01–1.22]), the association was not significant after 
adjusting for multiple testing. The ORs of IL-5 and RANTES, 
scaled by changes in standard deviation units of the ratio, 
were 2.29 and 1.61, respectively. Furthermore, the association 
of IL-5 with malaria was specific to RTS,S/AS01E vaccinees 
(P-adj = .049 for vaccination interaction; Supplementary Table 
6). No marker was associated with malaria in comparator 
vaccinees. Based on these results, we explored the association 
of IFN-γ/IL-5 ratio with malaria, and a higher ratio was found 
to be protective against malaria (P = .004; Supplementary 
Figure 4).
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The associations of nearly half of the markers with malaria 
varied between children and infants, including IFN-γ (Figure 4; 
Supplementary Table  6). In children, increases in CSP ratios 
of several markers significantly increased the odds of malaria. 
On the contrary, increases in CSP ratios of TH1 and proin-
flammatory cytokines IFN-γ, IL-15, and TNF and the granu-
locyte colony-stimulating factor (G-CSF) in infants protected 
from malaria. Sex of vaccinees did not confound associations 
between ratios and malaria—that is, neither impacted ORs nor 
P values (data not shown).
In secondary analyses (data not shown), we found that 
marker concentrations were not correlated with malaria.
Correlates of Clinical Malaria: Multiple-Marker Analysis
When analyzing combinations of marker ratios in models 
selected by elastic net, IFN-γ (OR, 0.90), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (OR, 
0.94), IL-15 (OR, 0.93), IL-5 (OR, 1.38), and RANTES (OR, 
1.15) were predictive of malaria in RTS,S/AS01E vaccinees 
(Supplementary Figure 5). Two components identified by 
PLS-DA were independently protective against malaria in 
RTS,S/AS01E vaccinees (Figure 5). In line with previous results, 
the markers that contributed more (loadings > <−0.3 or >0.3) to 
1 component were GM-CSF, IFN-γ, IL-5, and RANTES and to 
the other component were IL-15, IL-5, and RANTES.
DISCUSSION
We found that IL-5 CSP ratios at postvaccination increased 
the odds of malaria in RTS,S/AS01E-vaccinated children and 
infants, a result that could explain the lack of protection in 
numerous vaccinees through a different mechanism than the 
previously reported strain-specific VE in children [14]. In 
multimarker analysis, IL-5 and RANTES increased the odds 
of malaria in RTS,S/AS01E vaccinees, whereas the TH1-related 
markers IFN-γ, IL-15, and GM-CSF were correlated with RTS,S/
AS01E-induced protection. IFN-γ and IL-15 were also asso-
ciated with protection in single-marker analysis in infants, as 
well as TNF and G-CSF. Although associations of marker ratios 
with vaccination were comparable between age groups, associa-
tions with concentrations were significantly different for several 
markers. Proinflammatory and the above-reported protective 
markers were significantly higher in RTS,S/AS01E-vaccinated 
than in comparator-vaccinated children, but these differences 
were not observed in infants. These results suggest that RTS,S/
AS01E is less immunogenic in infants, and may explain the 
lower VE in this age group [12]. Of note, RTS,S/AS01 responses 
were higher for HBsAg than CSP. This may be due to a higher 
immunogenicity of HBsAg than CSP, to the higher proportion 
of HBsAg in the RTS,S vaccine, or to hepatitis B vaccination.
IL-5 is mainly produced by activated TH2 cells and restricted 
to effector memory T cells that are differentiated after recurrent 
antigenic exposure [15, 16]. IL-5 has never been examined in 
RTS,S trials, although IL-4, another TH2 cytokine, was previ-
ously found to be elevated in RTS,S-vaccinated infants [4]. In 
a preclinical study, the AS01B and AS02A adjuvants induced 
IL-5 in addition to IFN-γ responses [17]. To our knowledge, 
there is no epidemiological evidence of IL-5 association with 
occurrence of clinical malaria. Functional polarity between 
TH1 and TH2 responses could partially explain the association 
of IL-5 with malaria in RTS,S/AS01E vaccinees. IL-5+ TH2 cells 
probably constrain protective TH1 responses and inhibit several 
macrophage functions [18]. Exploratory analyses of IFN-γ/IL-5 
ratios indicate that a skewed response to TH2 increases the odds 
of malaria. Additionally, the effect of IL-5 in promoting eosin-
ophil responses [18] could contribute to the increased odds of 
malaria. Eosinophils have important regulatory functions and 
may restrict inflammation and increase plasma cell responses 
[19]. RANTES, the other marker that increased the odds of 
malaria, is produced by memory T cells and macrophages in 
PBMCs [18, 20] and is involved in chemoattraction of T cells 
and, together with IL-5, of eosinophils [18]. We speculate that 
IL-5 and RANTES in RTS,S/AS01E vaccinees could be acting 
together on eosinophils to regulate antibody responses through 
plasma cells, jeopardizing protective responses.
IFN-γ, mainly produced by T cells and natural killer (NK) 
cells, seems to be involved in the protection mediated by 
pre-erythrocytic vaccines [21]. CSP-specific IFN-γ T-cell and 
NK cell responses were elicited by RTS,S vaccination in adult 
challenge studies [22–24] and in clinical trials from endemic 
areas [4, 6, 7, 9], but their effect on protection remains unclear. 
TH1 responses are involved in protection against intracellular 
pathogens through cell-mediated immunity, and IFN-γ is cru-
cial for parasite killing through the induction of nitric oxide [18, 
21]. IL-15, a cytokine produced by dendritic cells and mono-
cytes in PBMCs, is important for activation of NK and T cells, 
including NK T cells and CD8+ T cells, which may be involved 
in RTS,S/AS01E-induced cellular responses to liver-stage par-
asites. GM-CSF, produced by TH1 and TH17, NK, and B cells 
and macrophages, induces effector functions in granulocytes, 
monocytes, macrophages, and eosinophils, is critical for den-
dritic cells, and increases IFN-γ secretion [25]. Therefore, IL-15 
and GM-CSF could contribute to induction or enhancement of 
TH1-mediated protective responses.
Detected age differences in immunogenicity are in line with 
immune ontogeny. Newborns have a biased cellular response 
toward a TH2 profile, due to diminished TH1 and proinflam-
matory responses that persist during the first months of life 
and increase around 12 months of age [26, 27]. Therefore, the 
age differences in RTS,S immunogenicity may be explained by 
diminished responsiveness in infants that may impact any vac-
cine [26, 27] depending on the adjuvant and antigen immuno-
genicity. Curiously, we detected similar marker differences in 
the mock stimulations, reflecting nonspecific responses upon 
RTS,S/AS01E vaccination. A nonspecific effect of RTS,S has not 
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been observed, but the nonspecific effect of other vaccines in 
early life has been described [28–30]. Surprisingly, despite low 
immunogenicity in infants, more markers were correlated with 
protection in infants than in children, including the TH1-related 
cytokines IFN-γ, IL-15, and TNF. On the contrary, in children, 
some markers including TNF were associated with increased 
Component 2 Component 3
VEGF
TNF
RANTES
MIP−1 β
MIP−1α
MIG
MCP−1
IP−10
IL−7
IL−5
IL−4
IL−2R
IL−2
IL−1RA
IL−1β
IL−17
IL−15
IL−13
IL−12
IL−10
IFN−γ
IFN−α
HGF
GM−CSF
G−CSF
FGF
Eotaxin
EGF
0.0 0.3−0.3 0.6−0.6 0.0 0.3−0.3 0.6−0.6
Loadings
Component 2 Component 3
Univariate models
OR (95% CI) 0.36 (0.2 - 0.64) 0.54 (0.32 - 0.92) 
AUC 0.714 0.675
Multivariate model
OR (95% CI) 0.35 (0.2 - 0.62) 0.46 (0.25 - 0.86) 
AUC 0.749
Figure 5. Association of combinations of circumsporozoite protein (CSP) marker ratios with clinical malaria with the combinations obtained through partial least squares 
(PLS) regression in RTS,S/AS01E vaccinees. Bars quantify the importance (loadings) of each marker (using CSP to control ratios) for specific marker combinations (PLS com-
ponent) that were significantly associated with clinical malaria (component 1 association with clinical malaria was not statistically significant, P = .2). Markers that sub-
stantially contributed for the component (loadings <-0.3 or >0.3) are highlighted in blue. Odds ratio and predictive accuracy (area under the receiver operating characteristic 
curve) from univariate and multivariate models with the selected combination of markers as variables are shown. N = 137 RTS,S/AS01E vaccinees. Abbreviations: AUC, area 
under the receiver operating characteristic curve; CI, confidence interval; EGF, epidermal growth factor; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating 
factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP, interferon-gamma-induced protein; MCP, 
monocyte chemoattractant protein; MIG, monokine induced by IFN-γ; MIP, macrophage inflammatory protein; OR, odds ratio; RANTES, regulated on activation normal T-cell 
expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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odds of malaria. Despite this apparent paradox, different levels 
of cytokines may have different effects. For instance, moder-
ate levels of cytokines like TNF have been described to control 
P. falciparum infection [31], but exacerbated levels are biomark-
ers of proinflammatory responses involved in pathogenesis 
of malaria [32]. Also, differences may be given by diverse cell 
origin as monocytes, macrophages, NK cells, and also effector 
memory and central memory T cells may produce it.
Several baseline marker ratios had an impact on postim-
munization ratios in children. Responses affected included the 
immunogenicity marker IL-2, the protective cytokines IFN-γ 
and IL-15, and IL-7, IFN-α, and VEGF, which were associated 
with higher odds of malaria in children. This suggests that 
immune status and previous responses to malaria and hepati-
tis B vaccine may influence RTS,S/AS01E immunogenicity. If 
malaria baseline immunity alters vaccine responses, it could 
further explain the lower VE in infants. Indeed, IgG data against 
CSP suggest that baseline levels have an impact on immuno-
genicity [12]. Also, baseline cell composition and inflam-
mation have previously been associated with RTS,S efficacy 
[33] and postvaccination responses in other vaccine studies 
[34–36]. Future work assessing cell phenotypes and activation, 
cytokine-expressing CD4+ T cells, and antibody responses to 
CSP and HBsAg at baseline may help confirm this hypothesis.
Imbalances in age distribution across sites and the nonavail-
ability of baseline samples in infants may limit the strength of 
some of our conclusions. Most children were from Bagamoyo 
and infants from Manhiça, but because malaria transmission 
was similar in both sites, it is unlikely that age differences were 
confounded by study site. Finally, our study did not include 
samples from areas of high endemicity, nor had information 
about other factors, for example, coinfections that could impact 
vaccine responses.
In summary, we identified 2 possible different and antagon-
istic cellular immune mechanisms induced by RTS,S/AS01E 
vaccination: IL-5 (and RANTES) TH2 responses associated 
with increased odds of malaria; and IFN-γ and other TH1-
related responses (GM-CSF, IL-15) associated with protection. 
Moreover, we detected lower induction of protective TH1 and 
proinflammatory responses by RTS,S/AS01E in infants than 
children, whereas TH2 responses were similar, which could 
contribute to the decreased VE in infants. Further analysis of 
cytokine-expressing cells together with isotypes and specifici-
ties of antibody responses to RTS,S/AS01E will clarify the role 
of these identified correlates in protection or lack thereof. Our 
findings may transcend antigen specificity and underscore the 
need to understand the impact of baseline immune status and 
factors that may modulate any pediatric vaccine responses in 
Africa. Our results reveal undesirable vaccine responses that 
may abrogate the protection of RTS,S/AS01E and other vac-
cines, but that might be overcome by improved formulations. 
Adjuvants that modulate the immune system to support a 
potent TH1 response during the first months of life and avoid 
counteracting responses may be required.
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